RDY
Dr. Reddy’s Laboratories Ltd
12.30$
-2.9%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
Dr. Reddy’s Laboratories Ltd (RDY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -927 million INR. Tick rows to compare them in a chart.
All figures in millions of INR.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17,926 | 4,737 | 136 | 8,496 | 9,316 | 6,620 | 21,996 | 14,629 | 15,573 | 10,908 | 15,438 | -927 | 40,992 | |
| 3,789 | 3,770 | 45 | 3,810 | 3,975 | 4,719 | 4,554 | 4,765 | 5,051 | 5,213 | 5,663 | 5,372 | 21,299 | |
| 103 | 99 | 97 | 101 | 107 | 103 | 113 | 112 | 100 | 20 | 94 | 97 | 311 | |
| -3,272 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2,609 | -11,855 | -33 | -13,141 | -7,784 | -9,648 | 584 | -8,191 | -2,556 | -8,126 | 7,779 | -11,997 | -14,900 | |
| 3,939 | 5,042 | 63 | 6,424 | 7,909 | 8,819 | 11,246 | 10,147 | 10,135 | 7,320 | 4,689 | 3,702 | 25,846 | |
| -12,753 | – | -142 | -20,248 | -19,071 | -5,458 | -13,300 | -19,192 | -9,543 | -10,292 | -28,222 | 3,836 | -44,221 | |
| 6,648 | 0.0 | 0.0 | 0.0 | 6,662 | 0.0 | 6,662 | 0.0 | 6,659 | 113 | 41 | 0.0 | 6,813 | |
| 765 | – | 805 | – | 157 | – | -1,389 | – | 288 | – | – | – | – | |
| -587 | – | – | – | 16,555 | 1,521 | -5,146 | -256 | 2,366 | 8,683 | 8,200 | -5,821 | 13,428 | |
| -7,036 | 5,282 | 1.7 | 9,541 | 16,150 | 590 | -7,370 | -1,203 | -5,323 | 7,777 | 8,738 | -7,117 | 4,075 | |
| 6,307 | -6,000 | -5.3 | -2,194 | 6,372 | 1,747 | 1,561 | -5,589 | 902 | 8,751 | -4,235 | -4,169 | 1,249 | |
| 13,987 | -305 | 73 | 2,072 | 1,407 | -2,199 | 10,750 | 4,482 | 5,438 | 3,588 | 10,749 | -4,629 | 15,146 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.